| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1010744586 |
| P356 | DOI | 10.2165/00002018-200629100-00003 |
| P698 | PubMed publication ID | 16970509 |
| P50 | author | Hermien E K De Walle | Q89635212 |
| Lolkje T W de Jong-van den Berg | Q60511270 | ||
| P2093 | author name string | Jacobus R B J Brouwers | |
| Fokaline Vroom | |||
| Mart A J F van de Laar | |||
| P2860 | cites work | Management and outcome of pregnancy in autoimmune hepatitis | Q28345133 |
| Developmental delay in fetal aminopterin/methotrexate syndrome | Q28369452 | ||
| Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? | Q28372707 | ||
| Cyclophosphamide for lupus during pregnancy | Q33368551 | ||
| Successful pregnancy in a neurologically impaired woman with Wilson's disease | Q73171077 | ||
| Multimodal cancer chemotherapy during the first and second trimester of pregnancy: a case report | Q73807343 | ||
| Infliximab treatment and pregnancy outcome in active Crohn's disease | Q74248650 | ||
| Cleft Palate and Toe Malformations in a Child With Fetal Methotrexate Exposure | Q79074837 | ||
| Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study | Q81074699 | ||
| Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis | Q81077329 | ||
| Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases | Q33579097 | ||
| Low dose weekly methotrexate in early pregnancy. A case series and review of the literature | Q34012302 | ||
| Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. | Q34184133 | ||
| Cyclophosphamide, methotrexate, and cytarabine embropathy: is apoptosis the common pathway? | Q34228830 | ||
| Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs. | Q34354377 | ||
| Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester | Q34523606 | ||
| Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease | Q34632049 | ||
| Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother | Q34740297 | ||
| A Study of 100 High Risk Lupus Pregnancies | Q35177106 | ||
| Case reports and case series from Lancet had significant impact on medical literature | Q36314363 | ||
| Adult and two children with fetal methotrexate syndrome | Q39465825 | ||
| Pregnancy in a patient with Wilson's disease treated with D-penicillamine and zinc sulfate. A case report and review of the literature | Q40590133 | ||
| Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy | Q40844061 | ||
| Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty‐three cases compared with a control group | Q41915008 | ||
| Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. | Q41919391 | ||
| Hydroxychloroquine in pregnant patients with systemic lupus erythematosus | Q41930084 | ||
| Pregnancy outcome following first trimester exposure to chloroquine | Q41942091 | ||
| Methotrexate exposure prior to and during pregnancy | Q42562797 | ||
| Population-based case control study of the safety of sulfasalazine use during pregnancy | Q43563783 | ||
| Wilson's disease in pregnancy: five successful consecutive pregnancies of the same woman. | Q43625265 | ||
| Neural tube defects in relation to use of folic acid antagonists during pregnancy | Q43625422 | ||
| Safety of azathioprine in pregnancy in inflammatory bowel disease | Q43727103 | ||
| Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases | Q43743058 | ||
| In utero first trimester exposure to low-dose methotrexate with increased fetal nuchal translucency and associated malformations | Q44063161 | ||
| The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study | Q44269245 | ||
| The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes | Q44300636 | ||
| Maternal Drug Use and Infant Cleft Lip/Palate with Special Reference to Corticoids | Q44631467 | ||
| Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy. | Q44694189 | ||
| Healthy offspring in parents both receiving thiopurines | Q44757560 | ||
| Disease specific problems related to drug therapy in pregnancy | Q45107051 | ||
| Antimalarial agents in pregnancy | Q45712596 | ||
| Folic acid sensitive birth defects in association with intrauterine exposure to folic acid antagonists | Q46501841 | ||
| Holoprosencephaly in a fetus with maternal medication of sulfasalazine in early gestation. A case report | Q47649137 | ||
| Infant with severe penicillamine embryopathy born to a woman with Wilson disease. | Q52088981 | ||
| Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. | Q52931732 | ||
| Guidelines for the management of rheumatoid arthritis: 2002 Update | Q56212157 | ||
| Prenatal exposure to penicillamine and oral clefts: Case report | Q60326029 | ||
| Systematic Identification of Drugs That Cause Birth Defects — A New Opportunity | Q60727536 | ||
| Prenatal diagnosis of methotrexate embryopathy | Q61820691 | ||
| Pregnancy and Wilson's disease | Q67944777 | ||
| Successful pregnancy after D-penicillamine therapy in a patient with Wilson's disease | Q68318619 | ||
| Pregnancy in a patient with treated Wilson's disease: a case report | Q68602678 | ||
| Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines | Q71098336 | ||
| Wilson's disease in pregnancy | Q71572935 | ||
| Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide | Q72235973 | ||
| Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody) | Q73165607 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 845-863 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Disease-modifying antirheumatic drugs in pregnancy: current status and implications for the future | |
| P478 | volume | 29 |
| Q37039184 | Fetal Anomalies in Rheumatoid Arthritis Patient Exposed to Low Dose Methotrexate |
| Q37854742 | Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy |
| Q36220831 | Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus |
| Q33445361 | Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases |
| Q36945003 | The safety of pharmacological therapies for gastrointestinal conditions encountered during pregnancy |
| Q84697085 | Treatment of cutaneous lupus erythematosus |
| Q41935321 | Use of antimalarials in dermatology |
Search more.